Galectin Therapeutics (GALT) Tops Q1 EPS by 2c

Galectin Therapeutics (NASDAQ: GALT) reported Q1 EPS of ($0.19), $0.02 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• UBS Starts CSE Global (CSE:SP) (CSYJF) at Buy
• Adobe (ADBE) PT Lowered to $315 at JPMorgan